NEW YORK ( TheStreet) -- The most common way to trade biotech run-ups is to find a stock with an upcoming FDA drug approval. Having an exact date provides run-up traders with a tight timeline to exit a trade before FDA makes it decision public. It's also possible to use the biotech run-up strategy to trade in stocks with pending clinical trial results.
The key to trading around a clinical trial is to only choose stocks where management has given a narrow timelines for the release of data. This does limit run-up trading opportunities because many companies prefer to be rather vague about predicting the completion of clinical trials. Trying to execute a profitable run-up trade in a stock with a clinical trial expected to report top-line results in the "second half of the year" or even the "fourth quarter" is just too risky.
On Sept. 5, Acadia announced the completion of patient enrollment in a phase III study of pimavanserin as a treatment for Parkinson's disease psychosis. Included in Acadia's press release on that day was a gift to all acolytes of the BioRunUp trading strategy:"Top-line results from this trial are expected to be announced by the end of November 2012." Thank you! Acadia's pimavanserin phase III study is very much a binary event for the company and will have a dramatic impact on the stock price. Acadia shares could easily double to $5 or more on positive results; likewise, the stock could fall below $1 per share if pimavanserin fails.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV